Amgenvs.Regeneron
AMGN vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 2.9× larger than Regeneron by market cap; Regeneron trades at the lower P/E (17.7 vs 25.5); year to date, Amgen leads (+23.0% vs −3.9%).
Side by side
| AMGN | REGN | |
|---|---|---|
| Market cap | $223B | $76.4B |
| Price | $407.44 | $739.57 |
| Today | −1.4% | −0.3% |
| Return YTD | +23.0% | −3.9% |
| Return 1Y | +36.9% | +27.2% |
| Since June 26, 2026 | +13.7% | +16.9% |
| P/E | 25.5 | 17.7 |
| P/S | 5.9 | 4.9 |
| P/B | 19.1 | 2.4 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More AMGN & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.